<DOC>
	<DOC>NCT02549963</DOC>
	<brief_summary>This is a prospective, multi-center, randomized, pilot study comparing the WATCHMAN left atrial appendage occlusion device with Rivaroxaban therapy in patients with non-valvular atrial fibrillation.</brief_summary>
	<brief_title>Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Paroxysmal, persistent or permanent nonvalvular atrial fibrillation Eligible for LAAO and longterm rivaroxaban therapy Calculated CHA2DS2VASc score of 2 or greater. Contraindicated/allergic to aspirin, clopidogrel and novel oral anticoagulants. Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment. History of atrial septal repair or has an atrial septal defect/patent foramen ovale device. History of valvular heart disease. Implanted mechanical valve prosthesis. New York Heart Association Class IV congestive heart failure or left ventricular ejection fraction less than 30%. Patient has left atrial/left atrial appendage thrombus screened by echocardiography Platelet&lt;100*109/L or hemoglobin&lt;100g/L Expected lifespan less than 1 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>